- Home
- PYPD vs GDTC Comparison
PYPD vs GDTC Comparison
Compare PYPD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- GDTC
- Stock Information
- Founded
- PYPD 2008
- GDTC 2018
- Country
- PYPD Israel
- GDTC Singapore
- Employees
- PYPD N/A
- GDTC N/A
- Industry
- PYPD Medical/Dental Instruments
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- GDTC Health Care
- Exchange
- PYPD Nasdaq
- GDTC Nasdaq
- Market Cap
- PYPD 30.1M
- GDTC 29.4M
- IPO Year
- PYPD 2020
- GDTC 2023
- Fundamental
- Price
- PYPD $2.99
- GDTC $2.80
- Analyst Decision
- PYPD Strong Buy
- GDTC Buy
- Analyst Count
- PYPD 2
- GDTC 1
- Target Price
- PYPD $10.50
- GDTC $5.00
- AVG Volume (30 Days)
- PYPD 18.1K
- GDTC 17.5K
- Earning Date
- PYPD 02-12-2025
- GDTC 01-01-0001
- Dividend Yield
- PYPD N/A
- GDTC N/A
- EPS Growth
- PYPD N/A
- GDTC N/A
- EPS
- PYPD N/A
- GDTC N/A
- Revenue
- PYPD N/A
- GDTC $330,254.00
- Revenue This Year
- PYPD N/A
- GDTC $14.71
- Revenue Next Year
- PYPD N/A
- GDTC N/A
- P/E Ratio
- PYPD N/A
- GDTC N/A
- Revenue Growth
- PYPD N/A
- GDTC N/A
- 52 Week Low
- PYPD $2.37
- GDTC $1.20
- 52 Week High
- PYPD $6.58
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- PYPD 49.42
- GDTC 55.34
- Support Level
- PYPD $2.89
- GDTC $2.50
- Resistance Level
- PYPD $3.27
- GDTC $2.77
- Average True Range (ATR)
- PYPD 0.28
- GDTC 0.23
- MACD
- PYPD 0.00
- GDTC 0.01
- Stochastic Oscillator
- PYPD 45.89
- GDTC 76.27
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.